Abstract
Nosocomial infections (NIs) are among the most difficult problems confronting clinicians who deal with severely ill patients. The incidence of these hospital-acquired infections varies with the size of hospitals, with specialities of wards, and with many other factors such as length of hospital stay, local trends in antibiotic usage, nursing and hygiene conditions, hospital design and geographical distribution of patients at risk. An average incidence of NI can be estimated at 5 to 10%, with higher rates in large university hospitals, reaching up to 28% in the intensive care unit (ICU). Changing epidemiology of NI and emerging resistance problems have resulted in evolving strategies of antibiotic usage in patients at risk. Several recent antibiotic resistance problems have been identified, for instance in Gram-positive organisms, and have been surveyed, in addition to those previously well known in Gram-negative bacilli. The choice of empiric antibiotic therapy for the treatment of any NI before microbiology is available has become a difficult challenge, requiring: (i) surveillance data on a regular basis of predominant organisms in units at risk; (ii) surveillance of the current resistance patterns of these organisms; (iii) identification of outbreaks involving the prevalent organisms, using modern molecular techniques for typing the strain and assess cross-contamination. In documented infection, monotherapy vs combination therapy has been often discussed in the treatment of serious Gram-negative hospital infections, but these concepts vary with the site of infection, the nature of organism involved and its pattern of resistance, the kind of antibiotic which may more or less quickly select resistant mutants. Antibiotic therapy concepts vary significantly between countries, and combinations either empirical or based on laboratory data are often preferred in European countries than in the US. Frequent collaborative studies and an increasing communication between experts of different countries, make guidelines and consensus conferences, established in a particular country, useful elsewhere and may contribute to improvement in the management of NI. Guidelines for the prevention and the control of NI are well established in many developed countries and they may have resulted in the improvement of the prevention and the treatment of NI. However, there is still potential progress that should be made, including individual preventive practices, improvement in nursing practices, control of antibiotic use, trend to shorten the hospital stay and early discharge from hospital, which results in significant cost savings.
Article PDF
Similar content being viewed by others
References
Jarvis WR, Wartone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 (ASuppl.): 19–24
Wolff M, Brun-Buisson C, Lode H, et al. The changing epidemiology of severe infections in the ICU. Clin Microb Infect 1997; 3 (1 Suppl.): S36–47
Aquino VM, Pappo A, Buchanan GR, et al. The changing epidemiology of bacteremia in neutropenic children with cancer. Pediatr Infect Dis 1995; 14: 140–3
Vincent JL, Bihari DJ, Sutter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995; 274: 639–45
National Nosocomial Infections Surveillance (NNIS) System, Centers of Disease Control and Prevention. National Nosocomial Infections (NNIS) report, data summary from October 1986–April 1996. Am J Infect Control 1996, 24: 380–8
Martone WJ, Jarvis WR, Edwards JR, et al. Incidence and nature of endemic and epidemic nosocomial infections. In: Bennett JV, Brachman PS, editors. Hospital infections. 4th ed. Philadelphia: Lippincott-Raven, 1998: 461–76
Brachman PS. Epidemiology of nosocomial infections. In: Bennett JV, Brachman PS, editors. Hospital infections. 4th ed. Philadelphia: Lippincott-Raven, 1998: 3–16
Emori TG, Gaynes RP. An overview of nosocomial infections including the role of the microbiology laboratory. Clin Micro-biol Rev 1993; 6: 428–42
Brun-Buisson C, Doyon F, Carlet J, French Bacteremia Sepsis Study Group. Bacteremia and severe sepsis in adults: a multi-center prospective survey in ICUs and wards of 24 hospitals. Am J Respir Crit Care Med 1996; 154: 617–24
Pittet D. Nosocomial bloodstream infections. In: Wenzel RP, editor. Prevention and control of nosocomial infections. 3rd ed. Baltimore: William and Wilkins, 1997: 711–69
Kluytmans J. Surgical infections including burns. In: Wenzel RP, editor. Prevention and control of nosocomial infections. 3rd ed. Baltimore: William and Wilkins, 1997: 841–65
Sherertz RJ, Garibaldi RA, Kaiser AB, et al. Consensus paper on the surveillance of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13: 599–605
Woods RK, Dellinger EP. Current guidelines for antibiotic prophylaxis of surgical wounds. Am Fam Physician 1998; 57: 2731–40
Weinstein RA, Hayden MK. Multiply drug resistant pathogens: epidemiology and control. In: Bennett JV, Brachman PS, editors. Hospital infections. 4th ed. Philadelphia: Lippincott-Raven, 1998: 215–36
Fraise AP. Epidemiology of resistance in intensive therapy units (ITUs). J Med Microbiol 1997; 46: 447–9
Bergogne-Bérézin E, Joly-Guillou ML. Hospital infection with Acinetobacter spp.: an increasing problem. J Hosp Infect 1991; 18 (ASuppl.): 250–5
Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care study. Eur J Clin Microbiol Infect Dis 1996; 15: 281–5
Gould IM. Risk factors for acquisition of multiply-drug-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1994; 13 (1 Suppl.): 30–8
Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin resistant and multidrug resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052–9
Péchère JC. Microbiology of nosocomial infections. Bull Acad Natl Med 1993; 177: 705–17
Howe RA, Brown NM, Spencer RC. The new threats of Gram-positive pathogens: re-emergence of things past. J Clin Pathol 1996; 49: 444–9
Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23: 1234–9
Noskin GA, Peterson LR, Warren JR. Enterococcus faecium. and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20: 296–301
Tan TQ, Eo Jr M, Ou CN, et al. Use of intravenous rifampin in neonates with persistent Staphylococcal bacteremia. Antimicrob Agents Chemother 1993; 37: 2401–6
Pujol M, Pena C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996; 100: 509–16
Coyle MD, Lipsky BA. Coryneform bacteria in infectious diseases: clinical and laboratory aspects. Clin Microbiol Rev 1990; 3: 227–46
Decré D, Buré A, Pangon B, et al. In vivo susceptibility of Rhodo-coccus equi to 27 antibiotics. J Antimicrob Chemother 1991; 28: 311–3
Penzak SR, Abate BJ. Stenotrophomonas (Xanthomonas) malto-philia: a multidrug resistant nosocomial pathogen. Pharmacotherapy 1997; 17: 293–301
Lecso-Bornet M, Bergogne-Bérézin E. Susceptibility of Stenotrophomonas maltophilia to three β-lactams and five β-lactam-β-lactamase inhibitor combinations. J Antimicrob Chemother 1997; 40: 717–20
Spencer RC. The emergence of epidemic, multiple-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burk-holderia (Pseudomonas) cepacia. J Hosp Infect 1995; (30 Suppl.): 453–64
Linden PK. Clinical implications of nosocomial Gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998; 104(5A): S24–33
Pitout JD, Sanders CC, Sanders Jr WE. Antimicrobial resistance with focus on beta-lactam resistance in Gram-negative bacilli. Am J Med 1997; 103: 51–9
Nordmann P, Guibert M. Extended spectrum β-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 1998; 42: 128–31
Spencer RC, Bauernfeind A, Garcia-Rodriguez J, et al. Surveillance of the current resistance of nosocomial pathogens to antibacterials. Clin Microb Infect 1997; 3 (1 Suppl.): S21–35
Bert F, Lambert-Zechovsky N. Antibiotic resistance patterns in Pseudomonas aeruginosa: an 8-year surveillance study in a French hospital. Int J Antimicrob Agents 1997; 9: 107–12
Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemio-logical features. Clin Microbiol Rev 1996; 9: 148–65
Cookson B, Morrison D, Marples R. Antibiotic resistance: nosocomial Gram-positive infection. J Med Microbiol 1997; 46: 439–42
Bauernfeind A, Wagner S, Jungwirth H, et al. A novel class C β-Lactamase (fox-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob Agents Chemother 1997; 41: 962–9
Pfaller MA, Cormican MG. Microbiology: the role of the clinical laboratory. In: Wenzel RP, editor. Prevention and control of nosocomial infections. 3rd ed. Baltimore: William and Wilkins, 1997: 96–118
Weber DJ, Rutala WA. Environmental issues and nosocomial infections. In: Wenzel RP, editor. Prevention and control of nosocomial infections. 3rd ed. Baltimore: William and Wilkins, 1997: 491–514
Kessler RE, Fung-Tong J. Susceptibility of bacterial isolates to β-lactam antibiotics from US clinical trials over a 5-year period. Am J Med 1996; 100(6A): 13S–9S
Itozaku GS, Quinn JP, Bell-Dixon C, et al. Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive-care-units: evaluation of a national postmarketing surveillance program. Clin Infect Dis 1996; 23: 779–84
Funke G, Von Graevenitz, A, Clarridge JE, et al. Clinical microbiology of coryneform bacteria. Clin Microbiol Rev 1997; 10: 125–59
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definition of sepsis and organ failure guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–74
Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531–9
Chastre J, Fagon JY, Trouillet JL. Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Clin Infect Dis 1995; 21 (3 Suppl.): S226–37
Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors and outcome of severe sepsis and septic shock in adult: a multicenter prospective study in intensive care units. JAMA 1995; 274: 968–74
Finegold SM. Aspiration pneumonia, lung abscess, and empyema. In: Pennington JE, editor. Respiratory infections: diagnosis and management. 3rd ed. New York: Raven Press Ltd, 1994; 311–22
Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime-amikacin vs ceftazidime-amikacin as empiric therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 1997; 24: 41–51
Glauser M, Boogaerts M, Cordonnier C, et al. Empiric therapy of bacterial infections in severe neutropenia. Clin Microb Infect 1997; 3 (A Suppl.): S77–86
Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551–73
Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs ceftriaxone/tobramycin for serious hospital acquired Gram-negative infections. Clin Infect Dis 1995; 20: 1217–28
Cometta A, Calandra T, Gaya H, et al. Monotherapy with mero-penem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108–15
Chow JW, Yu VL. Combination therapy versus monotherapy for Gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999; 11: 7–12
Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41: 1127–33
Arthur M, Reynolds PE, Depardieu F, et al. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996; 32: 11–6
Edmond MB, Ober JF, Weibaum DL. Vancomycin resistant Enterococcus faecium. bacteremia: risk factors for infection. Clin Infect Dis 1995; 20: 1126–33
Cercenado E, Eliopoulos GM, Wennersten CB, et al. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992; 36: 2201–3
Hancock RE, Bellido F. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation ceph-alosporins. J Antimicrob Chemother 1992; 29 (A Suppl.): 1–6
Sanders CC. Chromosomal cephalosporinases responsible for multiple resistance to newer β-lactam antibiotics. Ann Rev Microbiol 1987; 41: 573–93
Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multi-center, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastin. Antimicrob Agents Chemother 1994; 38: 547–57
American Thoracic Society. Hospital acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy and preventive strategies: a consensus statement. Am J Respir Care Med 1995; 153: 1711–25
Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med 1996; 156: 2121–6
Voss A, Doebbeling BN. The worldwide prevalence of methi-cillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1995; 5: 101–6
Graninger W, Wenisch C, Hasenhündl M. Treatment of staphylococcal infections. Curr Opin Infect Dis 1996; 8 (1 Suppl.): 520–8
Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135–6
Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997; 39 (A Suppl.): 1–16
Thys JP, Aoun M, Klastersky J. Local antibiotic therapy for bronchopulmonary infections. In: Pennington JE, editor. Respiratory infections: diagnosis and management. 3rd ed. New York: Raven Press Ltd, 1994: 741–66
Bergogne-Bérézin E, Vallée E. Pharmacokinetics in respiratory tissues and fluids. In: Pennington JE, editor. Respiratory infections: diagnosis and management. 3rd ed. New York: Raven Press Ltd, 1994: 715–40
Eisenberg J, Pepe M, Williams-Waaren J, et al. A comparison of peak sputum tobramycin concentration in patients with aerosolized tobramycin study group. Chest 1997; 111: 955–62
Guygenbichler JP, Berchtold D, Allerberger F, et al. In vitro and in vivo effect of antibiotics on catheters colonized by staphy-lococci. Eur J Clin Microbiol Infect Dis 1992; 11: 408–15
MacCabe WR, Jackson GG. Gram-negative bacteremia: etiology and ecology. Arch Intern Med 1962; 110: 847–55
Pitt TL, Barth AL. Pseudomonas aeruginosa and other medically important pseudomonas. In: Emmerson AM, Hawkey PM, Gillespie SH, editors. Principles and practice of clinical bacteriology. Chichester: Wiley and Sons, 1997: 494–517
Mozingo DW, Mc Manus AT, Pruitt Jr BA. Infections of burn wounds. In: Bennett JV, Brachman PS, editors. Hospital infections. 4th ed. Philadelphia: Lippincot-Raven Publishers, 1998: 587–97
Gaynes RP, Edwards JR, Jarvis WR, et al. Nosocomial infections among neonates in high risk nurseries in the United States. Pediatrics 1996; 98: 357–61
Schekler WE. The role of professional and regulatory organizations in infection control programs. In: Bennett JV, Brachman PS, editors. Hospital infections. 4th ed. Philadelphia: Lippincott-Raven, 1998: 175–80
Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge. JAMA 1996; 275: 234–40
CDC guidelines for the prevention and control of nosocomial infections. Hospital Infections Program. [statistical abstract]. USA: NTIS, 1997
CDC. Guidelines for prevention of nosocomial pneumonia. MMWR Morb Mortal Wkly Rep 1997; 46; 1–79
Ena J. Optimal use of antibiotics. In: Wenzel RP, editor. Prevention and control of nosocomial infections. 3rd ed. Baltimore: William and Wilkins, 1997: 323–38
Donta ST, Peduzzi P, Cross AS, et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. J Infect Dis 1996; 174: 537–43
Selective Decontamination of the Digestive Tract Trialists’ Collaborative Group. Meta-analysis of randomised controlled trials of selective decontamination of the digestive tract. BMJ 1993; 307: 525–32
Daschner F. Emergence of resistance during selective decontamination of the digestive tract. Eur J Clin Microbiol Infect Dis 1992; 11: 1–3
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bergogne-Bérézin, E. Current Guidelines for the Treatment and Prevention of Nosocomial Infections. Drugs 58, 51–67 (1999). https://doi.org/10.2165/00003495-199958010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199958010-00005